Women are more likely than men to seek medical care for weight-related concerns, to discuss body-weight changes with clinicians, and to pursue pharmacological options when lifestyle interventions fail
They are not suitable for every patient, but when used appropriately, they can complement a broader longevity program
Whilst originally developed for diabetes, GLP-1 receptor agonists induce significant weight loss, and with obesity affecting more than 1 billion people globally, GLP-1s represent the first meaningful drug treatment for this chronic condition in many decades
Strnad J, McDonnell PA, Riexinger DJ, Mapelli C, Cheng L, Gray H, et al
This makes Semaglutide a valuable option for individuals with diabetes who also have underlying cardiovascular conditions